| $350M | ||
| $172M | ||
| $115M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $495,080 | 2 | 10 |
Sells | $1,421,163 | 19 | 90 |
| Morrison Briggs | director | 2 | $495,080 | 0 | $0 | $495,080 |
| Loomis David K | Chief Accounting Officer | 0 | $0 | 4 | $46,898 | $-46,898 |
| Cacace Angela M | Chief Scientific Officer | 0 | $0 | 4 | $214,015 | $-214,015 |
| Saik Andrew | Chief Financial Officer | 0 | $0 | 3 | $218,210 | $-218,210 |
| Teel Randy | President and CEO | 0 | $0 | 4 | $226,477 | $-226,477 |
| Berkowitz Noah | Chief Medical Officer | 0 | $0 | 3 | $249,410 | $-249,410 |
| Houston John G | director | 0 | $0 | 1 | $466,154 | $-466,154 |
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Over the last 12 months, insiders at Arvinas, Inc. have bought $495,080 and sold $1.42M worth of Arvinas, Inc. stock.
On average, over the past 5 years, insiders at Arvinas, Inc. have bought $495,080 and sold $13.51M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Morrison Briggs (director) — $495,080.
The last purchase of 20,000 shares for transaction amount of $268,070 was made by Morrison Briggs (director) on 2026‑03‑06.
| 2026-06-24 | Sale | Saik Andrew | Chief Financial Officer | 5,696 0.0088% | $8.16 | $46,474 | +6.34% | |
| 2026-06-17 | Sale | Cacace Angela M | Chief Scientific Officer | 2,576 0.004% | $7.59 | $19,565 | +10.17% | |
| 2026-05-21 | Sale | Teel Randy | President and CEO | 2,209 0.0034% | $9.04 | $19,962 | -7.80% | |
| 2026-05-11 | Sale | Teel Randy | President and CEO | 9,657 0.0155% | $9.94 | $95,965 | -11.59% | |
| 2026-05-11 | Sale | Saik Andrew | Chief Financial Officer | 11,139 0.0179% | $9.94 | $110,693 | -11.59% | |
| 2026-05-11 | Sale | Berkowitz Noah | Chief Medical Officer | 11,108 0.0179% | $9.94 | $110,385 | -11.59% | |
| 2026-05-11 | Sale | Cacace Angela M | Chief Scientific Officer | 9,657 0.0155% | $9.94 | $95,965 | -11.59% | |
| 2026-05-11 | Sale | Loomis David K | VP, Chief Accounting Officer | 1,919 0.0031% | $9.94 | $19,070 | -11.59% | |
| 2026-03-18 | Sale | Berkowitz Noah | Chief Medical Officer | 6,435 0.0102% | $11.10 | $71,431 | -17.31% | |
| 2026-03-06 | Morrison Briggs | director | 20,000 0.0307% | $13.40 | $268,070 | -33.20% | ||
| 2026-02-27 | Sale | Houston John G | director | 35,297 0.0478% | $13.21 | $466,154 | -31.42% | |
| 2026-02-23 | Sale | Teel Randy | President and CEO | 4,786 0.0064% | $12.16 | $58,198 | -25.20% | |
| 2026-02-23 | Sale | Cacace Angela M | Chief Scientific Officer | 3,609 0.0049% | $12.16 | $43,885 | -25.20% | |
| 2026-02-23 | Sale | Loomis David K | Chief Accounting Officer | 1,108 0.0015% | $12.16 | $13,473 | -25.20% | |
| 2026-02-13 | Sale | Berkowitz Noah | Chief Medical Officer | 5,685 0.0079% | $11.89 | $67,595 | -20.60% | |
| 2026-02-13 | Sale | Saik Andrew | Chief Financial Officer | 5,134 0.0071% | $11.89 | $61,043 | -20.60% | |
| 2026-02-13 | Sale | Teel Randy | President and CEO | 4,403 0.0061% | $11.89 | $52,352 | -20.60% | |
| 2026-02-13 | Sale | Cacace Angela M | Chief Scientific Officer | 4,592 0.0064% | $11.89 | $54,599 | -20.60% | |
| 2026-02-13 | Sale | Loomis David K | Chief Accounting Officer | 1,016 0.0014% | $11.89 | $12,080 | -20.60% | |
| 2025-11-07 | Sale | Loomis David K | Chief Accounting Officer | 230 0.0003% | $9.89 | $2,275 | -0.24% |
| Houston John G | director | 1122183 1.7392% | $9.48M | 1 | 12 | +24.92% |
| Teel Randy | President and CEO | 285009 0.4417% | $2.41M | 0 | 4 | |
| Berkowitz Noah | Chief Medical Officer | 191395 0.2966% | $1.62M | 0 | 4 | |
| Saik Andrew | Chief Financial Officer | 187432 0.2905% | $1.58M | 0 | 4 | |
| Cacace Angela M | Chief Scientific Officer | 180390 0.2796% | $1.52M | 0 | 6 | |
| Morrison Briggs | director | 96021 0.1488% | $811,377.45 | 3 | 2 | |
| Loomis David K | VP, Chief Accounting Officer | 40193 0.0623% | $339,630.85 | 0 | 7 | |
| RA CAPITAL MANAGEMENT, LLC | 3138412 4.8642% | $26.52M | 1 | 0 | +24.92% | |
| SHANNON TIMOTHY M | director | 1653128 2.5621% | $13.97M | 5 | 11 | +45.5% |
| Flynn James E | 10 percent owner | 411245 0.6374% | $3.48M | 1 | 0 | +24.92% |
| Loven Jakob | director | 312500 0.4843% | $2.64M | 1 | 0 | +24.92% |
| Ratcliffe Liam | director | 185686 0.2878% | $1.57M | 3 | 10 | +24.96% |
| Cassidy Sean A | Chief Financial Officer | 181916 0.2819% | $1.54M | 1 | 13 | +24.92% |
| Taylor Ian | President, R&D | 159121 0.2466% | $1.34M | 1 | 13 | +66.46% |
| 5AM VENTURES III, L.P. | 10 percent owner | 91162 0.1413% | $770,318.90 | 0 | 4 | |
| Peck Ronald | Chief Medical Officer | 67516 0.1046% | $570,510.20 | 0 | 8 | |
| Kennedy Edward Moore Jr. | director | 42718 0.0662% | $360,967.10 | 2 | 0 | +24.92% |
| Margus Bradley Albert | director | 2000 0.0031% | $16,900.00 | 1 | 5 | +24.92% |
$3,611,891 | 113 | 13.40% | $613.89M | |
$2,481,409 | 33 | 201.68% | $474.1M | |
$31,271,604 | 28 | 28.69% | $481.36M | |
$22,020,194 | 25 | 38.25% | $590.55M | |
$112,238,340 | 19 | 39.16% | $467.51M | |
$129,396,927 | 18 | 48.82% | $565.33M | |
Arvinas, Inc. (ARVN) | $133,809,976 | 13 | 31.29% | $545.2M |
$6,385,840 | 12 | 0.69% | $590.04M | |
$57,263,116 | 11 | -8.37% | $614.38M | |
$130,748,265 | 10 | 53.98% | $560.31M | |
$75,069,528 | 10 | 19.77% | $605.26M | |
$5,529,561 | 8 | 5.30% | $502.06M | |
$62,616,785 | 8 | -7.00% | $548.15M | |
$17,675,244 | 7 | 92.20% | $464.2M | |
$21,792,890 | 6 | 75.72% | $472.68M | |
$4,745,999 | 5 | -4.91% | $494.94M | |
$164,999,952 | 5 | -44.44% | $499.66M | |
$208,592 | 4 | 11.22% | $498.7M | |
$2,720,023 | 3 | -11.76% | $560.67M |
| Increased Positions | 100 | +39.06% | 11M | +16.69% |
| Decreased Positions | 111 | -43.36% | 20M | -31.1% |
| New Positions | 31 | New | 5M | New |
| Sold Out Positions | 35 | Sold Out | 10M | Sold Out |
| Total Postitions | 245 | -4.3% | 55M | -14.4% |
| Vanguard Group Inc | $98,197.00 | 13.38% | 8.56M | -831,929 | -8.86% | 2025-09-30 |
| Blackrock, Inc. | $78,030.00 | 10.63% | 6.8M | -86,514 | -1.26% | 2025-09-30 |
| Logos Global Management Lp | $63,945.00 | 8.71% | 5.58M | +2M | +68.94% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $38,392.00 | 5.23% | 3.35M | +1M | +55.63% | 2025-09-30 |
| Millennium Management Llc | $24,449.00 | 3.33% | 2.13M | +233,483 | +12.3% | 2025-09-30 |
| State Street Corp | $21,484.00 | 2.93% | 1.87M | +140,763 | +8.13% | 2025-09-30 |
| Geode Capital Management, Llc | $19,157.00 | 2.61% | 1.67M | +85,087 | +5.37% | 2025-09-30 |
| Morgan Stanley | $19,066.00 | 2.6% | 1.66M | +78,492 | +4.96% | 2025-09-30 |
| Tcg Crossover Management, Llc | $18,551.00 | 2.53% | 1.62M | +2M | New | 2025-09-30 |
| New Leaf Venture Partners, L.L.C. | $18,188.00 | 2.48% | 1.59M | 0 | 0% | 2025-09-30 |